Loading...
Market
Outcome of next major VK2735 trial by mid-2025?
2
Resolution / Starting Odds
Positive efficacy and safety • 25%
Positive efficacy, negative safety • 25%
Negative efficacy • 25%
Inconclusive • 25%
Clinical trial results published by Viking Therapeutics
Story
Viking Therapeutics' Obesity Pill Shows 8.2% Weight Loss, Stock Surges 20%
Nov 4, 2024, 01:52 AM
Viking Therapeutics' experimental obesity pill, VK2735, has shown promising results in recent studies. The oral formulation demonstrated a weight loss of 8.2% and 6.8% in separate trials, with safety and tolerability comparable to a placebo. The drug's efficacy and safety profile position it as a potential competitor to existing treatments from Novo Nordisk and Eli Lilly. Viking's market cap is around $10 billion, with the total addressable market for obesity treatments estimated at over $200 billion. The company's stock surged 20% in overnight trading following the release of the data. The 28-day Phase 1 trial showed positive results even at a 100mg dose. Future trials are expected to further validate the drug's effectiveness and safety.
View original story
Similar markets
Exceeds expectations • 25%
Meets expectations • 25%
Below expectations • 25%
Study discontinued • 25%
Granted in 2024 • 25%
Granted in 2025 • 25%
Not granted by 2025 • 25%
Other designation received • 25%
Phase 2 trial results • 25%
Partnership announcement • 25%
Regulatory submission • 25%
Other milestone • 25%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Safety established • 25%
Preliminary efficacy demonstrated • 25%
Both safety and efficacy demonstrated • 25%
No significant results • 25%